Claims
- 1. A compound represented by structure 1:
- 2. The compound of claim 1, wherein X is —C(O)—.
- 3. The compound of claim 1, wherein Y is independently for each occurrence (NR)n.
- 4. The compound of claim 1, wherein Z is independently for each occurrence C(R).
- 5. The compound of claim 1, wherein W is independently for each occurrence (CR2)m.
- 6. The compound of claim 1, wherein G is selected, independently for each occurrence, from the group consisting of H, —COOH, —SR, and 2-R-tetrazol-5-yl.
- 7. The compound of claim 1, wherein m and n are integers selected, independently for each occurrence, from 1 and 2.
- 8. The compound of claim 1, wherein X is —C(O)—; and Y is independently for each occurrence (NR)n.
- 9. The compound of claim 1, wherein X is —C(O)—; and Z is independently for each occurrence C(R).
- 10. The compound of claim 1, wherein X is —C(O)—; and W is independently for each occurrence (CR2)m.
- 11. The compound of claim 1, wherein X is —C(O)—; and G is selected, independently for each occurrence, from the group consisting of H, —COOH, —SR, and 2-R-tetrazol-5-yl.
- 12. The compound of claim 1, wherein X is —C(O)—; Y is independently for each occurrence (NR)n; and Z is independently for each occurrence C(R).
- 13. The compound of claim 1, wherein X is —C(O)—; Y is independently for each occurrence (NR)n; and W is independently for each occurrence (CR2)m.
- 14. The compound of claim 1, wherein X is —C(O)—; Y is independently for each occurrence (NR)n; and G is selected, independently for each occurrence, from the group consisting of H, —COOH, —SR, and 2-R-tetrazol-5-yl.
- 15. The compound of claim 1, wherein X is —C(O)—; Y is independently for each occurrence (NR)n; Z is independently for each occurrence C(R); and W is independently for each occurrence (CR2)m.
- 16. The compound of claim 1, wherein X is —C(O)—; Y is independently for each occurrence (NR)n; W is independently for each occurrence (CR2)m; and G is selected, independently for each occurrence, from the group consisting of H, —COOH, —SR, and 2-R-tetrazol-5-yl.
- 17. The compound of claim 1, wherein X is —C(O)—; Y is independently for each occurrence (NR)n; Z is independently for each occurrence C(R); W is independently for each occurrence (CR2)m; and G is selected, independently for each occurrence, from the group consisting of H, —COOH, —SR, and 2-R-tetrazol-5-yl.
- 18. A compound represented by structure 2:
- 19. The compound of claim 18, wherein X is —C(O)—.
- 20. The compound of claim 18, wherein Y is independently for each occurrence (NR)n.
- 21. The compound of claim 18, wherein G is selected, independently for each occurrence, from the group consisting of —COOH, —SO3H, —P(O)(OH)2, and 2-R-tetrazol-5-yl.
- 22. The compound of claim 18, wherein G is selected, independently for each occurrence, from the group consisting of —COOH, and 2-R-tetrazol-5-yl.
- 23. The compound of claim 18, wherein X is —C(O)—; and Y is independently for each occurrence (NR)n.
- 24. The compound of claim 18, wherein X is —C(O)—; Y is independently for each occurrence (NR)n; and G is selected, independently for each occurrence, from the group consisting of —COOH, —SO3H, —P(O)(OH)2, and 2-R-tetrazol-5-yl.
- 25. The compound of claim 18, wherein X is —C(O)—; Y is independently for each occurrence (NR)n; and G is selected, independently for each occurrence, from the group consisting of —COOH, and 2-R-tetrazol-5-yl.
- 26. The compound of claim 1 or 18, wherein the compound is a single stereoisomer.
- 27. The compound of claim 1 or 18, wherein the compound is a ligand for a metabotropic glutamate receptor.
- 28. The compound of claim 1 or 18, wherein the compound is an agonist of a metabotropic glutamate receptor.
- 29. The compound of claim 1 or 18, wherein the compound is a antagonist of a metabotropic glutamate receptor.
- 30. The compound of claim 1 or 18, wherein the compound is a ligand for a single subtype of metabotropic glutamate receptor.
- 31. The compound of claim 1 or 18, wherein the compound is an agonist of a single subtype of metabotropic glutamate receptors.
- 32. The compound of claim 1 or 18, wherein the compound is an antagonist of a single subtype of metabotropic glutamate receptors.
- 33. The compound of claim 1 or 18, wherein the compound is an inhibitor of NAALADase.
- 34. A pharmaceutical composition, comprising a compound of claim 1 or 18; and pharmaceutically acceptable excipient.
- 35. A method of inhibiting NAALADase in a mammal, comprising the step of administering to a mammal a therapeutically effective amount of a compound of claim 1 or 18.
- 36. A method of agonising a metabotropic glutamate receptor in a mammal, comprising the step of administering to a mammal a subject a therapeutically effective amount of a compound of claim 1 or 18.
- 37. A method of antagonising a metabotropic glutamate receptor in a mammal, comprising the step of administering to a mammal a therapeutically effective amount of a compound of claim 1 or 18.
- 38. A method of agonising a single subtype of metabotropic glutamate receptor in a mammal, comprising the step of administering to a mammal a therapeutically effective amount of a compound of claim 1 or 18.
- 39. A method of antagonising a single subtype of metabotropic glutamate receptor in a mammal, comprising the step of administering to a mammal a therapeutically effective amount of a compound of claim 1 or 18.
RELATED APPLICATIONS
[0001] This application is a continuation-in-part of U.S. patent application Ser. No. 09/559,978, filed Apr. 27, 2000.
GOVERNMENT SUPPORT
[0002] This invention was made with support from the National Institutes of Health and Department of Defense; the government, therefore, has certain rights in the invention.
Provisional Applications (3)
|
Number |
Date |
Country |
|
60131627 |
Apr 1999 |
US |
|
60166915 |
Nov 1999 |
US |
|
60188031 |
Mar 2000 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09662767 |
Sep 2000 |
US |
Child |
10374765 |
Feb 2003 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09559978 |
Apr 2000 |
US |
Child |
09662767 |
Sep 2000 |
US |